ICON applies real-world health research network to improve clinical development
TriNetX is a research network and technology platform connecting ICON to the Electronic Medical Record (EMR) systems of a rapidly expanding network of healthcare organisations representing over 57 million patient lives globally. Through TriNetX, ICON is conducting real-time feasibility reviews by analysing patient populations with search criteria across multiple data points and assessing the inclusion and exclusion criteria that have the most impact on patient recruitment. Each data point in the TriNetX system can be traced to healthcare organisations who have the ability to identify individual patients, enabling ICON to develop virtual patient cohorts that can be found in real-world clinical trial settings. ICON incorporates the use of EMRs in all new client studies and has already conducted over 300 feasibility reviews utilizing TriNetX across multiple therapeutic areas.
The use of TriNetX is another example of ICON's leadership in applying
targeted technology to help customers reduce the time and cost of their
development programmes through more accurate patient identification and
faster patient recruitment. It follows ICON's
application of cognitive computing capabilities to clinical trial
feasibility and patient recruitment. ICON's ability to recruit
patients is also strengthened through a wholly owned site network -
Commenting on today's announcement, ICON's Chief Operating Officer, Dr.
"ICON is leveraging the health research network to help pharmaceutical,
biotechnology and medical device clients bring new therapies to market
faster. TriNetX is pleased to support a world leader improving the
efficiency of drug development," said
Further information is available at www.iconplc.com.
TriNetX is the worldwide health research network of healthcare organizations, biopharmaceutical companies and contract research organizations used to enhance clinical trial design and accelerate patient recruitment. TriNetX enables researchers to find the right patients at the right sites for clinical trials. For more information, visit http://www.trinetx.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in
+44 (0) 207 067 0272
News Provided by Acquire Media